Table 3.

NRI and IDI Analysis for Predicting Major Bleeding Risk in Anticoagulated Patients With AF^a

Study	Contrast	NRI Analysis	IDI Analysis
Apostolakis 201213	HAS‐BLED	vs HEMORR2HAGES: +6.8%, P = 0.42; vs ATRIA: +9.0%, P = 0.33	NA
Apostolakis 201316	HAS‐BLED	vs CHADS2: +13.0%, P = 0.001; vs CHA2DS2‐VASc: +10.0%, P = 0.04	NA
Roldán 201317	HAS‐BLED	vs ATRIA: +19.6%, P = 0.019	vs ATRIA: +7.0%, P = 0.001
Roldán 201318	HAS‐BLED	vs CHADS2: +38.62%, P < 0.001; vs CHA2DS2‐VASc: +37.6%, P < 0.001	vs CHADS2: +10.0%, P < 0.001; vs CHA2DS2‐VASc: +12.0%, P < 0.001
Barnes 201419	HAS‐BLED	vs HEMORR2HAGES: +26.0%, P = 0.006; vs ATRIA: +31.0%, P = 0.001; vs CHADS2: +58.0%, P < 0.001; vs CHA2DS2‐VASc: +36.0%, P < 0.001	NA

Abbreviations: AF, atrial fibrillation; ATRIA, Anticoagulation and Risk Factors in Atrial Fibrillation; CHADS₂, congestive heart failure, hypertension, age ≥75 years, DM, stroke/TIA history; CHA₂DS₂‐VASc, congestive heart failure/LVEF ≤40%, hypertension, age ≥75 y, DM, stroke/TIA/TE history, vascular disease, age 65–74 y, sex (F); DM, diabetes mellitus; F, female; HAS‐BLED, hypertension, abnormal liver/renal function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly; HEMORR₂HAGES, hepatic or renal disease, ethanol abuse, malignancy, older age, reduced platelet count or function, re‐bleeding risk, hypertension (uncontrolled), anemia, genetic factors, excessive fall risk, stroke; IDI, integrated discrimination improvement; INR, international normalized ratio; LVEF, left ventricular ejection fraction; NA, not available; NRI, net reclassification improvement; TE, thromboembolism; TIA, transient ischemic attack.

^aA P value <0.05 demonstrated that the HAS‐BLED score had statistically significant positive NRI or IDI values when compared with other risk scores.